Vical grants Merck rights to gene delivery technology
13th Sep 2005, 06:46 GMT
Vical Incorporated has agreed to grant Merck & Co renewable options for rights to use Vical's patented non-viral gene delivery technology for additional cancer targets.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol